These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 21831900

  • 21. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer.
    Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendröi A, Schmid KW, Shariat SF, Kramer G, vom Dorp F, Rübben H, Szarvas T.
    Urol Oncol; 2014 Jul; 32(5):663-9. PubMed ID: 24814404
    [Abstract] [Full Text] [Related]

  • 22. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH.
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [Abstract] [Full Text] [Related]

  • 23. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.
    Harutyunyan M, Gøtze JP, Winkel P, Johansen JS, Hansen JF, Jensen GB, Hilden J, Kjøller E, Kolmos HJ, Gluud C, Kastrup J.
    Immunobiology; 2013 Jul; 218(7):945-51. PubMed ID: 23294528
    [Abstract] [Full Text] [Related]

  • 24. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
    Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W, Spriggs D, Fleisher M, Thaler H, Dupont J.
    Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
    [Abstract] [Full Text] [Related]

  • 25. Serum YKL-40/chitinase 3-like protein 1 level is an independent predictor of atherosclerosis development in patients with obstructive sleep apnea syndrome.
    Bakırcı EM, Ünver E, Değirmenci H, Kıvanç T, Günay M, Hamur H, Büyüklü M, Ceyhun G, Topal E, Çoban TA.
    Turk Kardiyol Dern Ars; 2015 Jun; 43(4):333-9. PubMed ID: 26142786
    [Abstract] [Full Text] [Related]

  • 26. Elevated plasma YKL-40 as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension.
    Chen G, Yang T, Gu Q, Ni XH, Zhao ZH, Ye J, Meng XM, Liu ZH, He JG, Xiong CM.
    Respirology; 2014 May; 19(4):608-15. PubMed ID: 24689969
    [Abstract] [Full Text] [Related]

  • 27. Serum YKL-40 levels as a novel marker of inflammation in patients with endometriosis.
    Ural UM, Tekin YB, Cüre M, Şahin FK.
    Clin Exp Obstet Gynecol; 2015 May; 42(4):495-7. PubMed ID: 26411218
    [Abstract] [Full Text] [Related]

  • 28. Pretransplant serum human chitinase-like glycoprotein YKL-40 concentrations independently predict bronchiolitis obliterans development in lung transplant recipients.
    Jaksch P, Taghavi S, Klepetko W, Salama M.
    J Thorac Cardiovasc Surg; 2014 Jul; 148(1):273-81. PubMed ID: 24685381
    [Abstract] [Full Text] [Related]

  • 29. Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer.
    Kemik P, Saatli B, Yıldırım N, Kemik VD, Deveci B, Terek MC, Koçtürk S, Koyuncuoğlu M, Saygılı U.
    Gynecol Oncol; 2016 Jan; 140(1):64-9. PubMed ID: 26607777
    [Abstract] [Full Text] [Related]

  • 30. Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.
    Verschuere T, Van Woensel M, Fieuws S, Lefranc F, Mathieu V, Kiss R, Van Gool SW, De Vleeschouwer S.
    J Neurooncol; 2013 Oct; 115(1):9-17. PubMed ID: 23824536
    [Abstract] [Full Text] [Related]

  • 31. Elevation in circulating YKL-40 concentration in patients with cerebrovascular disease.
    Xu X, Ma H, Xu J, Huang H, Wu X, Xiong Y, Zhan H, Huang F.
    Bosn J Basic Med Sci; 2014 Aug 14; 14(3):120-4. PubMed ID: 25172968
    [Abstract] [Full Text] [Related]

  • 32. Resveratrol represses YKL-40 expression in human glioma U87 cells.
    Zhang W, Murao K, Zhang X, Matsumoto K, Diah S, Okada M, Miyake K, Kawai N, Fei Z, Tamiya T.
    BMC Cancer; 2010 Oct 28; 10():593. PubMed ID: 21029458
    [Abstract] [Full Text] [Related]

  • 33. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival.
    Johansen JS, Brasso K, Iversen P, Teisner B, Garnero P, Price PA, Christensen IJ.
    Clin Cancer Res; 2007 Jun 01; 13(11):3244-9. PubMed ID: 17545529
    [Abstract] [Full Text] [Related]

  • 34. Association of serum YKL-40 level with tumor burden and metastatic stage of prostate cancer.
    Özdemir E, Çiçek T, Kaya MO.
    Urol J; 2012 Jun 01; 9(3):568-73. PubMed ID: 22903479
    [Abstract] [Full Text] [Related]

  • 35. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients.
    Pirotte BJ, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O, Bruneau M, Rorive S, David P, Brotchi J.
    Neurosurgery; 2009 Mar 01; 64(3):471-81; discussion 481. PubMed ID: 19240609
    [Abstract] [Full Text] [Related]

  • 36. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.
    Yamac D, Ozturk B, Coskun U, Tekin E, Sancak B, Yildiz R, Atalay C.
    Adv Ther; 2008 Aug 01; 25(8):801-9. PubMed ID: 18670741
    [Abstract] [Full Text] [Related]

  • 37. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
    Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, Larsen J, von der Maase H.
    J Clin Oncol; 2006 Feb 10; 24(5):798-804. PubMed ID: 16391295
    [Abstract] [Full Text] [Related]

  • 38. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
    Roslind A, Johansen JS, Christensen IJ, Kiss K, Balslev E, Nielsen DL, Bentzen J, Price PA, Andersen E.
    Int J Cancer; 2008 Feb 15; 122(4):857-63. PubMed ID: 17957792
    [Abstract] [Full Text] [Related]

  • 39. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer.
    Liu X, Zhang Y, Zhu Z, Ha M, Wang Y.
    Med Oncol; 2014 Aug 15; 31(8):85. PubMed ID: 24996799
    [Abstract] [Full Text] [Related]

  • 40. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
    Vachher M, Arora K, Burman A, Kumar B.
    J Cell Biochem; 2020 Apr 15; 121(4):3010-3023. PubMed ID: 31710121
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.